Skip to main content
. Author manuscript; available in PMC: 2013 Mar 15.
Published in final edited form as: Clin Cancer Res. 2011 Dec 21;18(6):1790–1797. doi: 10.1158/1078-0432.CCR-11-2361

Figure 2.

Figure 2

In vitro analyses of EGFR exon 19 insertion mutations. (A) Ba/F3 cells harboring different exon 19 insertions are sensitive to gefitinib and afatinib, similar to exon 19 deletion (E746_A750del) Ba/F3 cells. Exon 20 insertion cells (Y764_V765insHH) are resistant to both drugs. (B) NIH-3T3 cells harboring exon 19 insertions demonstrate a marked reduction in phospho-EGFR when treated with either gefitinib or afatinib, consistent with the growth assays (A).